Semisynthesis reveals apoptin as a tumour-selective protein prodrug that causes cytoskeletal collapse
Jasmine Wyatt1,2, Yuen Ka Chan1, Mateusz Hess2
1Department of Molecular Oncology, King's College London Guy's Hospital Campus, Hodgkin Building London SE1 1UL UK mahvash.tavassoli@kcl.ac.uk.
Abstract:
Apoptin is a small viral protein capable of inducing cell death selectively in cancer cells. Despite its potential as an anticancer agent, relatively little is known about its mechanism of toxicity and cancer-selectivity. Previous experiments suggest that cancer-selective phosphorylation modulates apoptin toxicity, although a lack of chemical tools has hampered the dissection of underlying mechanisms. Here, we describe structure-function studies with site-specifically phosphorylated apoptin (apoptin-T108ph) in living cells which revealed that Thr108 phosphorylation is the selectivity switch for apoptin toxicity. Mechanistic investigations link T108ph to actin binding, cytoskeletal disruption and downstream inhibition of anoikis-resistance as well as cancer cell invasion. These results establish apoptin as a protein pro-drug, selectively activated in cancer cells by phosphorylation, which disrupts the cytoskeleton and promotes cell death. We anticipate that this mechanism provides a framework for the design of next generation anticancer proteins with enhanced selectivity and potency.
Insights
Apoptin protein selectively kills cancer cells by becoming activated through phosphorylation. This process disrupts the cancer cell cytoskeleton, leading to cell death and reduced invasion, offering a new anticancer strategy.
Area of Science:
- Molecular Biology
- Biochemistry
- Cell Biology
Background:
- Apoptin is a viral protein with selective cancer cell-killing properties.
- Its precise mechanism of action and cancer selectivity remain incompletely understood.
- Phosphorylation is hypothesized to regulate apoptin's toxicity and selectivity.
Purpose of the Study:
- To investigate the role of site-specific phosphorylation in apoptin's anticancer activity.
- To elucidate the molecular mechanisms underlying apoptin's cancer selectivity.
- To explore the potential of apoptin as a targeted anticancer therapeutic.
Main Methods:
- Site-specific phosphorylation of apoptin at Thr108 (apoptin-T108ph).
- Structure-function studies in living cancer cells.
- Investigation of cellular pathways including actin binding and cytoskeletal integrity.
- Analysis of anoikis resistance and cancer cell invasion.
Main Results:
- Thr108 phosphorylation acts as a critical selectivity switch for apoptin toxicity.
- Phosphorylated apoptin (apoptin-T108ph) binds to actin and disrupts the cytoskeleton.
- This disruption inhibits anoikis resistance and reduces cancer cell invasion.
- Apoptin functions as a pro-drug activated by cancer-specific phosphorylation.
Conclusions:
- Cancer-selective phosphorylation activates apoptin, enhancing its anticancer potency.
- The mechanism involves cytoskeletal disruption, leading to cancer cell death.
- This study provides a foundation for developing novel, highly selective protein-based anticancer agents.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Apoptosis
The Extrinsic Apoptotic Pathway
Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized...
Caspases
Anaphase Promoting Complex


